Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review and evidence map of randomised controlled trials

Apaydin EA, Richard J, Miner SA, Waymouth M, Roberts D, Vockley J, Richardson AS. Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review[...]

Interrelationships Between Kansas City Cardiomyopathy Questionnaire Domains, Age, and Sex for Patients With Heart Failure: Findings From the CHAMP-HF and CORC Registries

Girard AA, Jones PG, Fu Z, Sherrod CF 4th, Cantu Martinez O, Greene SJ, Bachmann JM, Fonarow GC, Butler J, Spertus JA, Arnold SV. Interrelationships[...]

Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream

Eibl G, Hines OJ, Rozengurt E. Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream. Cancer Prev[...]